Press-release for stocks

Prices are updated after-hours

treatment crawled time : 23:00

save search

Fracking Water Treatment Market size to record USD 1.20 billion growth from 2023-2027, Adoption of supercritical carbon in fracking is one of the key market trends, Technavio
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
XYL | News | $130.72 1.35% 0.0% 950K

Producer Manufacturing

| 2.13% | O: 0.38% H: 0.0% C: -1.77%
water one treatment key growth market

POWERFLEET ANNOUNCES RESTATEMENT OF ACCOUNTING TREATMENT OF LEGACY CONVERTIBLE PREFERRED STOCK INSTRUMENT, WHICH HAS NO ADVERSE IMPACT ON PREVIOUSLY REPORTED REVENUE, CASH FLOW OR ADJUSTED EBITDA
Published: 2024-04-05 (Crawled : 23:00) - prnewswire.com
PWFL | $4.2 3.45% 3.33% 730K

Electronic Technology

| Email alert Add to watchlist
MIXT | $14.55 0.0% 530K

Technology Services

| Email alert Add to watchlist
treatment impact flow

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Published: 2024-04-04 (Crawled : 23:00) - biospace.com/
DTIL | $10.33 6.72% 6.29% 31K

Health Technology

| -33.74% | O: -2.33% H: 1.64% C: -4.91%
ecur-506 fda drug treatment clearance for application trial

Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Published: 2024-04-02 (Crawled : 23:00) - biospace.com/
VNDA | $4.63 -3.54% -3.67% 1.4M

Health Technology

| 12.38% | O: -2.43% H: 0.0% C: -2.74%
fanapt fda approval treatment

Global Infectious Enteritis Treatment Market Report 2024: A USD$937.7 Million Market by 2034 - Antibiotics Segment Dominates the Market
Published: 2024-03-29 (Crawled : 23:00) - prnewswire.com
ARDX | $6.38 -2.0% -2.04% 3.8M

Health Technology

| Email alert Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| Email alert Add to watchlist
GLAXF | News | $20.305 -14.18% 630

Health Technology

| Email alert Add to watchlist
ABT | News | $107.59 0.49% -0.09% 3.8M

Health Technology

| Email alert Add to watchlist
GSK | News | $41.24 1.6% 0.0% 2.3M

Health Technology

| Email alert Add to watchlist
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| Email alert Add to watchlist
report million treatment antibiotics global market

Global Particle Therapy Market Analysis and Forecasts, 2023-2033 : Revolutionizing Cancer Treatment, Particle Therapy's Rise in External Beam Radiotherapy
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
BSGM | $1.45 -6.75% -7.24% 75K

Health Technology

| 108.16% | O: 3.94% H: 4.19% C: -10.55%
cancer global therapy market

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Published: 2024-03-26 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K

Health Technology

| -2.21% | O: 2.21% H: 5.76% C: 5.76%
mn-166 patent japan macular treatment

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M

Health Technology

| 1.25% | O: 0.38% H: 0.24% C: -0.21%
fda group treatment hypertension

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
STOK | $11.24 -0.09% -0.09% 600K

Health Technology

| 78.57% | O: -0.16% H: 8.11% C: 3.34%
stk-001 first treatment therapeutics potential

Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $24.4 0.95% 0.94% 420K

Health Technology

| -11.14% | O: 1.49% H: 2.98% C: -0.43%
fda pruritus approval treatment livmarli

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K

Health Technology

| -12.87% | O: -0.93% H: 3.2% C: 2.66%
fda brukinsa approval treatment

Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Published: 2024-03-04 (Crawled : 23:00) - prnewswire.com
EYEN | $0.55 6.49% 6.09% 880K

Health Technology

| -76.32% | O: -2.19% H: 0.0% C: -21.08%
fda ocular approval treatment pharmaceuticals therapeutics

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.95 -0.05% -0.05% 870K

Health Technology

| -13.97% | O: 0.88% H: 1.12% C: -0.73%
INCY | $51.62 -0.58% -0.58% 2.5M

Health Technology

| -14.67% | O: 0.2% H: 1.37% C: 0.58%
drug disease review food treatment grants

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-02-20 (Crawled : 23:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -4.44% | O: 0.12% H: 0.0% C: 0.0%
tecvayli fda approved treatment

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaCompany on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCL
Published: 2024-02-08 (Crawled : 23:00) - biospace.com/
CRVS | $1.53 6.25% 5.88% 140K

Health Technology

| -26.09% | O: 0.0% H: 0.0% C: -3.38%
drug granted cell treatment pharmaceuticals designation trial

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XCUR 4 | $0.5397 -3.7% 6K

Commercial Services

| -0.74% | O: 1.1% H: 1.82% C: 1.76%
hepatitis patent license treatment therapeutics agreement

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M

Health Technology

| -4.66% | O: 0.07% H: 1.4% C: 0.92%
positive treatment fibrosis trials results

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
Published: 2024-02-01 (Crawled : 23:00) - prnewswire.com
TYRA | $16.355 5.52% 5.23% 150K

Health Technology

| 25.9% | O: 12.61% H: 17.41% C: 14.81%
tyra-300 fda rare disease achondroplasia treatment designation

NexPoint Residential Trust Announces 2023 Dividend Income Tax Treatment
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
NXRT | $33.02 0.95% 0.0% 96K

Finance

| 4.16% | O: 0.19% H: 0.76% C: -3.81%
treatment trust

NexPoint Real Estate Finance Announces 2023 Dividend Income Tax Treatment
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
NREF | $13.13 0.69% 0.0% 30K

Finance

| -13.45% | O: -1.12% H: 0.85% C: -2.87%
treatment